Crestline Management LP boosted its position in Insmed Incorporated (NASDAQ:INSM) by 5.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 68,856 shares of the biopharmaceutical company’s stock after buying an additional 3,437 shares during the quarter. Crestline Management LP owned approximately 0.09% of Insmed worth $2,147,000 at the end of the most recent quarter.
A number of other institutional investors have also recently made changes to their positions in INSM. Janus Henderson Group PLC increased its holdings in Insmed by 140.2% in the third quarter. Janus Henderson Group PLC now owns 3,960,748 shares of the biopharmaceutical company’s stock valued at $123,615,000 after buying an additional 2,312,045 shares during the last quarter. BlackRock Inc. grew its holdings in shares of Insmed by 11.7% during the fourth quarter. BlackRock Inc. now owns 7,830,604 shares of the biopharmaceutical company’s stock valued at $244,159,000 after purchasing an additional 817,915 shares during the last quarter. Nexthera Capital LP grew its holdings in shares of Insmed by 246.5% during the fourth quarter. Nexthera Capital LP now owns 498,921 shares of the biopharmaceutical company’s stock valued at $15,556,000 after purchasing an additional 354,921 shares during the last quarter. Alyeska Investment Group L.P. bought a new position in shares of Insmed during the third quarter valued at approximately $9,210,000. Finally, Ameriprise Financial Inc. grew its holdings in shares of Insmed by 308.3% during the third quarter. Ameriprise Financial Inc. now owns 298,513 shares of the biopharmaceutical company’s stock valued at $9,316,000 after purchasing an additional 225,394 shares during the last quarter. 99.10% of the stock is owned by hedge funds and other institutional investors.
INSM has been the subject of several recent research reports. BidaskClub raised Insmed from a “sell” rating to a “hold” rating in a report on Friday, December 22nd. Zacks Investment Research lowered Insmed from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. Robert W. Baird reaffirmed a “positive” rating and set a $42.00 target price (up from $32.00) on shares of Insmed in a report on Thursday, January 4th. HC Wainwright reaffirmed a “buy” rating and set a $35.00 target price on shares of Insmed in a report on Thursday, January 4th. Finally, Credit Suisse Group initiated coverage on Insmed in a report on Wednesday, January 17th. They set a “neutral” rating and a $31.00 target price for the company. One analyst has rated the stock with a sell rating, four have assigned a hold rating and six have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $36.67.
Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Friday, February 23rd. The biopharmaceutical company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.18). sell-side analysts forecast that Insmed Incorporated will post -3.65 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Insmed Incorporated (INSM) Shares Bought by Crestline Management LP” was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2018/03/14/insmed-incorporated-insm-shares-bought-by-crestline-management-lp.html.
Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).
Want to see what other hedge funds are holding INSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed Incorporated (NASDAQ:INSM).
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.